How selective antagonists and genetic modification have helped characterise the expression and functions of vascular P2Y receptors.

Kennedy C, Chootip K, Mitchell C, Syed NH, Tengah A (2013) P2X and P2Y nucleotide receptors as targets in cardiovascular disease. Future Med Chem 5:431–439. https://doi.org/10.4155/fmc.13.6

doi: 10.4155/fmc.13.6 pubmed: 23495690

Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kügelgen I et al (2020) Update of P2Y Receptor Pharmacology : IUPHAR Review 27. Br J Pharmacol 177:2413–2433. https://doi.org/10.1111/bph.15005

doi: 10.1111/bph.15005 pubmed: 32037507 pmcid: 7205808

Illes P, Müller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, Kennedy C et al (2021) Update of P2X receptor properties and their pharmacology; IUPHAR review. Br J Pharmacol 178:489–514. https://doi.org/10.1111/bph.15299

doi: 10.1111/bph.15299 pubmed: 33125712

Erlinge D, Burnstock G (2008) P2 receptors in cardiovascular regulation and disease. Purinergic Signal 4:1–20. https://doi.org/10.1007/s11302-007-9078-7

doi: 10.1007/s11302-007-9078-7 pubmed: 18368530

Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 87:659–797. https://doi.org/10.1152/physrev.00043.2006

doi: 10.1152/physrev.00043.2006 pubmed: 17429044

Burnstock G (2017) Purinergic signaling in the cardiovascular system. Circ Res 120:207–228. https://doi.org/10.1161/CIRCRESAHA.116.309726

doi: 10.1161/CIRCRESAHA.116.309726 pubmed: 28057794

Strassheim D, Verin A, Batori R, Nijmeh H, Burns N, Kovacs-Kasa A, Umapathy NS, Kotamarthi J, Gokhale YS, Karoor V, Stenmark KR, Gerasimovskaya E (2020) P2Y purinergic receptors, endothelial dysfunction, and cardiovascular diseases. Int J Mol Sci 21:1–21. https://doi.org/10.3390/ijms21186855

doi: 10.3390/ijms21186855

Kennedy C, Burnstock G (1985) Evidence for two types of P

doi: 10.1016/0014-2999(85)90112-8

Burnstock G, Kennedy C (1986) A dual function for adenosine triphosphate in the regulation of vascular tone: excitatory cotransmitter with noradrenaline from perivascular nerves and locally released inhibitory intravascular agent. Circ Res 58:319–330. https://doi.org/10.1161/01.res.58.3.319

doi: 10.1161/01.res.58.3.319 pubmed: 3013455

Kennedy C, Delbro D, Burnstock G (1985) P

doi: 10.1016/0014-2999(85)90055-x

Kennedy C (2021) That was then, this is now: the development of our knowledge and understanding of P2 receptor subtypes. Purinergic Signal 17:9–23. https://doi.org/10.1007/s11302-021-09763-0

doi: 10.1007/s11302-021-09763-0 pubmed: 33527235 pmcid: 7954963

Burnstock G, Knight GE (2004) Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240:31–304. https://doi.org/10.1016/S0074-7696(04)40002-3

doi: 10.1016/S0074-7696(04)40002-3 pubmed: 15548415

Alexander SP, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL et al (2023) The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. Br J Pharmacol 180(Suppl 2):S23–S144. https://doi.org/10.1111/bph.16177

doi: 10.1111/bph.16177 pubmed: 38123151

Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International Union of Pharmacology. Update of the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281–341. https://doi.org/10.1124/pr.58.3.3

doi: 10.1124/pr.58.3.3 pubmed: 16968944

Kennedy C (2015) ATP as a cotransmitter in the autonomic nervous system. Auton Neurosci Basic Clinical 191:2–15. https://doi.org/10.1016/j.autneu.2015.04.004

doi: 10.1016/j.autneu.2015.04.004

van der Giet M, Schmidt S, Tölle M, Jankowski J, Schlüter H, Zidek W, Tepel M (2002) Effects of dinucleoside polyphosphates on regulation of coronary vascular tone. European J Pharmacol 448(2–3):207–213. https://doi.org/10.1016/s0014-2999(02)01986-6

doi: 10.1016/s0014-2999(02)01986-6

Kaneshiro T, Saitoh S, Machii H, Yamaguchi O, Ishibashi T, Maruyama Y, Takeishi Y (2010) Metabolic regulation of coronary vascular tone: role of hydrogen peroxide, purinergic components, and angiotensin. European J Pharmacol 645(1–3):127–134. https://doi.org/10.1016/j.ejphar.2010.07.025

doi: 10.1016/j.ejphar.2010.07.025

Gorman MW, Ogimoto K, Savage MV, Jacobson KA, Feigl EO (2003) Nucleotide coronary vasodilation in guinea pig hearts. Am J Physiol Heart Circ Physiol 285(3):H1040-1047. https://doi.org/10.1152/ajpheart.00981.2002

doi: 10.1152/ajpheart.00981.2002 pubmed: 12763753

Bender SB, Berwick ZC, Laughlin MH, Tune JD (2011) Functional contribution of P2Y

doi: 10.1152/japplphysiol.00946.2011 pubmed: 21940850 pmcid: 3233891

Zhou Z, Merkus D, Cheng C, Duckers HJ, Jan Danser AH, Duncker DJ (2013) Uridine adenosine tetraphosphate is a novel vasodilator in the coronary microcirculation which acts through purinergic P1 but not P2 receptors. Pharmacol Res 67(1):10–17. https://doi.org/10.1016/j.phrs.2012.09.011

doi: 10.1016/j.phrs.2012.09.011 pubmed: 23063485

Kaiser RA, Buxton IL (2002) Nucleotide-mediated relaxation in guinea-pig aorta: selective inhibition by MRS2179. Br J Pharmacol 135(2):537–545. https://doi.org/10.1038/sj.bjp.0704476

doi: 10.1038/sj.bjp.0704476 pubmed: 11815389 pmcid: 1573141

Guns PJ, Korda A, Crauwels HM, Van Assche T, Robaye B, Boeynaems JM, Bult H (2005) Pharmacological characterization of nucleotide P2Y receptors on endothelial cells of the mouse aorta. Br J Pharmacol 146:288–295. https://doi.org/10.1038/sj.bjp.0706326

doi: 10.1038/sj.bjp.0706326 pubmed: 15997227 pmcid: 1576272

Buvinic S, Briones R, Huidobro-Toro JP (2002) P2Y

doi: 10.1038/sj.bjp.0704789 pubmed: 12110609 pmcid: 1573418

Dales MO, Mitchell C, Gurney AM, Drummond RM, Kennedy C (2022) Characterisation of P2Y receptor subtypes mediating vasodilation and vasoconstriction of rat pulmonary artery using selective antagonists. Purinergic Signal 18(4):515–528. https://doi.org/10.1007/s11302-022-09895-x

doi: 10.1007/s11302-022-09895-x pubmed: 36018534 pmcid: 9832182

Xu HL, Ye S, Baughman VL, Feinstein DL, Pelligrino DA (2005) The role of the glia limitans in ADP-induced pial arteriolar relaxation in intact and ovariectomized female rats. Am J Physiol Heart Circ Physiol 288(1):H382-388. https://doi.org/10.1152/ajpheart.00727.2004

doi: 10.1152/ajpheart.00727.2004 pubmed: 15374830

Geddawy A, Shimosato T, Tawa M, Imamura T, Okamura T (2010) Comparison of endothelium-related responses to nucleotides of dog and monkey cerebral arteries. J Pharmacol Sci 112(3):378–381. https://doi.org/10.1254/jphs.09316sc

doi: 10.1254/jphs.09316sc pubmed: 20168045

Guns PJ, Van Assche T, Fransen P, Robaye B, Boeynaems JM, Bult H (2006) Endothelium-dependent relaxation evoked by ATP and UTP in the aorta of P2Y

doi: 10.1038/sj.bjp.0706642 pubmed: 16415908 pmcid: 1616985

Wihlborg AK, Malmsjö M, Eyjolfsson A, Gustafsson R, Jacobson K, Erlinge D (2003) Extracellular nucleotides induce vasodilatation in human arteries via prostaglandins, nitric oxide and endothelium-derived hyperpolarising factor. Br J Pharmacol 138(8):1451–1458. https://doi.org/10.1038/sj.bjp.0705186

doi: 10.1038/sj.bjp.0705186 pubmed: 12721100 pmcid: 1573798

Kwan HY, Cheng KT, Ma Y, Huang Y, Tang NL, Yu S, Yao X (2010) CNGA2 contributes to ATP-induced noncapacitative Ca

doi: 10.1159/000235969 pubmed: 19729961

Olivecrona GK, Gotberg M, Harnek J, Wang L, Jacobson KA, Erlinge D (2004) Coronary artery reperfusion: The ADP receptor P2Y

doi: 10.1007/s11302-004-4742-7 pubmed: 18404401 pmcid: 2096564

Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK (1998) Agonist action of adenosine triphosphates at the human P2Y

doi: 10.1124/mol.54.6.1118 pubmed: 9855642

Buvinic S, Poblete MI, Donoso MV, Delpiano AM, Briones R, Miranda R, Huidobro-Toro JP (2006) P2Y

doi: 10.1113/jphysiol.2006.105882 pubmed: 16543271 pmcid: 1779721

Malheiros-Lima MR, Antunes VR, Takakura AC, Moreira TS (2019) Hypertension and sympathetic nervous system overactivity rely on the vascular tone of pial vessels of the rostral ventrolateral medulla in spontaneously hypertensive rats. Exp Physiol 105(1):65–74. https://doi.org/10.1113/EP088169

doi: 10.1113/EP088169 pubmed: 31785061

Mitchell C, Syed NH, Tengah A, Gurney AM, Kennedy C (2012) Identification of contractile P2Y

doi: 10.1124/jpet.112.198051

Kylhammar D, Bune LT, Rådegran G (2014) P2Y

doi: 10.1007/s00421-014-2921-y

Govindan S, Taylor EJ, Taylor CW (2010) Ca

doi: 10.1111/j.1476-5381.2010.00763.x pubmed: 20649593 pmcid: 2913105

Kindon N, Davis A, Dougall I, Dixon J, Johnson T, Walters I, Thom S, McKechnie K, Meghani P, Stocks MJ (2017) From UTP to AR-C118925, the discovery of a potent non nucleotide antagonist of the P2Y

doi: 10.1016/j.bmcl.2017.09.043 pubmed: 28958619

Rafehi M, Burbiel JC, Attah IY, Abdelrahman A, Müller CE (2017) Synthesis, characterization, and in vitro evaluation of the selective P2Y

doi: 10.1007/s11302-016-9542-3 pubmed: 27766552

Rafehi M, Neumann A, Baqi Y, Malik EM, Wiese M, Namasivayam V, Müller CE (2017) Molecular recognition of agonists and antagonists by the nucleotide-activated G protein-coupled P2Y

doi: 10.1021/acs.jmedchem.7b00854 pubmed: 28938069

Rafehi M, Müller CE (2018) Tools and drugs for uracil nucleotide-activated P2Y receptors. Pharmacol Ther 190:24–80. https://doi.org/10.1016/j.pharmthera.2018.04.002

doi: 10.1016/j.pharmthera.2018.04.002 pubmed: 29660366

Matsumoto T, Kojima M, Takayanagi K, Katome T, Taguchi K, Kobayashi T (2020) Impaired UTP-induced relaxation in the carotid arteries of spontaneously hypertensive rats. Purinergic Signal 16:453–461. https://doi.org/10.1007/s11302-020-09721-2

doi: 10.1007/s11302-020-09721-2 pubmed: 32862324 pmcid: 7524952

Lee MD, Wilson C, Saunter CD, Kennedy C, Girkin JM, McCarron JG (2018) Spatially-structured cell populations process multiple sensory signals in parallel in intact vascular endothelium. Sci Signal 11:eaar4411. https://doi.org/10.1126/scisignal.aar4411

doi: 10.1126/scisignal.aar4411 pubmed: 30563865 pmcid: 6420068

Leong IL, Tsai TY, Wong KL, Shiao LR, Cheng KS, Chan P, Leung YM (2018) Valproic acid inhibits ATP-triggered Ca

doi: 10.1111/fcp.12381

Wang S, Iring A, Strilic B, Albarrán Juárez J, Kaur H, Troidl K, Tonack S, Burbiel JC, Müller CE, Fleming I, Lundberg JO, Wettschureck N, Offermanns S (2015) P2Y

doi: 10.1172/JCI81067 pubmed: 26168216 pmcid: 4563756

Muoboghare MO, Drummond R, Kennedy C (2019) Characterisation of P2Y

doi: 10.1111/bph.14715 pubmed: 31116875 pmcid: 6637037

Raqeeb A, Sheng J, Ao N, Braun AP (2011) Purinergic P2Y

doi: 10.1016/j.ceca.2011.02.008 pubmed: 21414662

Wang S, Chennupati R, Kaur H, Iring A, Wettschureck N, Offermanns S (2016) Endothelial cation channel PIEZO1 controls blood pressure by mediating flow-induced ATP release. J Clin Invest 126(12):4527–4536. https://doi.org/10.1172/JCI87343

doi: 10.1172/JCI87343 pubmed: 27797339 pmcid: 5127677

Bintig W, Begandt D, Schlingmann B, Gerhard L, Pangalos M, Dreyer L, Hohnjec N, Couraud PO, Romero IA, Weksler BB, Ngezahayo A (2012) Purine receptors and Ca

doi: 10.1007/s11302-011-9262-7 pubmed: 21956217

Ding L, Ma W, Littmann T, Camp R, Shen J (2011) The P2Y

doi: 10.1074/jbc.M111.235176 pubmed: 21652710 pmcid: 3143661

Haanes KA, Spray S, Syberg S, Jørgensen NR, Robaye B, Boeynaems JM, Edvinsson L (2016) New insights on pyrimidine signalling within the arterial vasculature - Different roles for P2Y

doi: 10.1016/j.yjmcc.2016.01.025 pubmed: 26827897

Chen X, Qian S, Hoggatt A, Tang H, Hacker TA, Obukhov AG, Herring PB, Seye CI (2017) Endothelial Cell-Specific Deletion of P2Y

doi: 10.1161/ATVBAHA.116.308561 pubmed: 27856454

Bar I, Guns PJ, Metallo J, Cammarata D, Wilkin F, Boeynams JM, Bult H, Robaye B (2008) Knockout mice reveal a role for P2Y

doi: 10.1124/mol.108.046904 pubmed: 18523137

Gergs U, Rothkirch D, Hofmann B, Treede H, Robaye B, Simm A, Müller CE, Neumann J (2018) Mechanism underlying the contractile activity of UTP in the mammalian heart. European J Pharmacol 830:47–58. https://doi.org/10.1016/j.ejphar.2018.04.013

doi: 10.1016/j.ejphar.2018.04.013

Henriquez M, Fonseca M, Perez-Zoghbi JF (2018) Purinergic receptor stimulation induces calcium oscillations and smooth muscle contraction in small pulmonary veins. J Physiol 596:2491–2506. https://doi.org/10.1113/JP274731

doi: 10.1113/JP274731 pubmed: 29790164 pmcid: 6023829

Kauffenstein G, Drouin A, Thorin-Trescases N, Bachelard H, Robaye B, D’Orléans-Juste P, Marceau F, Thorin E, Sévigny J (2010) NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc Res 85:204–213. https://doi.org/10.1093/cvr/cvp265

doi: 10.1093/cvr/cvp265 pubmed: 19640930

Qian S, Hoggatt A, Jones-Hall YL, Ware CF, Herring P, Seye CI (2016) Deletion of P2Y

doi: 10.1016/j.vph.2016.06.001 pubmed: 27355755 pmcid: 5453728

Jalkanen J, Yegutkin GG, Hollmén M, Aalto K, Kiviniemi T, Salomaa V, Jalkanen S, Hakovirta H (2015) Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis. Circ Res 116(7):1206–1215. https://doi.org/10.1161/CIRCRESAHA.116.305715

doi: 10.1161/CIRCRESAHA.116.305715 pubmed: 25645301

Robson SC, Sévigny J, Zimmermann H (2006) The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. Purinergic Signal 2:409–430. https://doi.org/10.1096/fj.06-7050com

doi: 10.1096/fj.06-7050com pubmed: 18404480 pmcid: 2254478

Agca Y, Qian S, Agca C, Seye CI (2016) Direct Evidence for P2Y

doi: 10.1159/000449059 pubmed: 27723650

Horckmans M, Robaye B, Léon-Gόmez E, Lantz N, Unger P, Dol-Gleizes F, Clouet S, Cammarata D, Schaeffer P, Savi P, Gachet C, Balligand JL, Dessy C, Boeynaems JM, Communi D (2012) P2Y

doi: 10.1007/s10456-012-9265-1 pubmed: 22437266

Nishimura A, Sunggip C, Tozaki-Saitoh H, Shimauchi T, Numaga-Tomita T, Hirano K, Ide T, Boeynaems JM, Kurose H, Tsuda M, Robaye B, Inoue K, Nishida M (2016) Purinergic P2Y

doi: 10.1126/scisignal.aac9187 pubmed: 26787451

Alsaqati M, Chan SL, Ralevic V (2014) Investigation of the functional expression of purine and pyrimidine receptors in porcine isolated pancreatic arteries. Purinergic Signal 10:241–249. https://doi.org/10.1007/s11302-013-9403-2.CHECK

doi: 10.1007/s11302-013-9403-2.CHECK pubmed: 24310605

Abbas ZSB, Latif ML, Dovlatova N, Fox SC, Heptinstall S, Dunn WR, Ralevic V (2018) UDP-sugars activate P2Y

doi: 10.1016/j.vph.2017.12.063 pubmed: 29253618 pmcid: 5906693

Kobayashi S, Matsumoto T, Ando M, Iguchi M, Watanabe S, Taguchi K, Kobayashi T (2018) UDP-induced relaxation is enhanced in aorta from female obese Otsuka Long-Evans Tokushima Fatty rats. Purinergic Signal 14(1):91–96. https://doi.org/10.1007/s11302-017-9595-y

doi: 10.1007/s11302-017-9595-y pubmed: 29188550

Kauffenstein G, Tamareille S, Prunier F, Roy C, Ayer A et al (2016) Central role of P2Y

doi: 10.1161/ATVBAHA.116.307739 pubmed: 27255725 pmcid: 5350073

Roy C, Tabiasco J, Caillon A, Delneste Y, Merot J, Favre J, Guihot AL, Martin L, Nascimento DC, Ryffel B, Robson SC, Sévigny J, Henrion D, Kauffenstein G (2018) Loss of vascular expression of nucleoside triphosphate diphosphohydrolase-1/CD39 in hypertension. Purinergic Signal 14(1):73–82. https://doi.org/10.1007/s11302-017-9597-9

doi: 10.1007/s11302-017-9597-9 pubmed: 29236227

Jagadeesh T, Choudhury S, Gari M, Singh V, Shukla A, Garg SK (2023) Sepsis modulates aortic AT1 and P2Y

doi: 10.1080/10799893.2023.2204960 pubmed: 37099407

Stachon P, Peikert A, Michel NA, Hergeth S, Marchini T, Wolf D, Dufner B, Hoppe N, Ayata CK, Grimm M, Cicko S, Schulte L, Reinöhl J, von zur Muhlen C, Bode C, Idzko M, Zirlik A (2014) P2Y

Zhou Z, Chrifi I, Xu Y, Pernow J, Duncker DJ, Merkus D, Cheng C (2016) Uridine adenosine tetraphosphate acts as a proangiogenic factor in vitro through purinergic P2Y receptors. Am J Physiol Heart Circ Physiol 311(1):H299-309. https://doi.org/10.1152/ajpheart.00578.2015

doi: 10.1152/ajpheart.00578.2015 pubmed: 27233766

Ng PY, McIntosh KA, Hargrave G, Ho KH, Paul A, Plevin R (2018) Inhibition of cytokine-mediated JNK signalling by purinergic P2Y

doi: 10.1016/j.cellsig.2018.07.016 pubmed: 30076967

Piollet M, Sturza A, Chadet S, Gabillard-Lefort C, Benoist L, Muntean DM, Aburel OM, Angoulvant D, Ivanes F (2021) P2Y11 Agonism Prevents Hypoxia/Reoxygenation- and Angiotensin II-Induced Vascular Dysfunction and Intimal Hyperplasia Development. Int J Mol Sci 22(2):855. https://doi.org/10.3390/ijms22020855

doi: 10.3390/ijms22020855 pubmed: 33467058 pmcid: 7829863

Kuang Y, Liu H, Guo S, Wang Y, Zhang H, Qiao Y (2019) The antagonist of P2Y

doi: 10.1080/21691401.2019.1610412 pubmed: 31066305

Zhang X, Bishawi M, Zhang G, Prasad V, Salmon E, Breithaupt JJ, Zhang Q, Truskey GA (2020) Modeling early stage atherosclerosis in a primary human vascular microphysiological system. Nat Commun 11(1):5426. https://doi.org/10.1038/s41467-020-19197-8

doi: 10.1038/s41467-020-19197-8 pubmed: 33110060 pmcid: 7591486

Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller JR, Wright AC, Bergmann JE, Gaitanaris GA (2003) The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci USA 100:4903–4908. https://doi.org/10.1073/pnas.0230374100

doi: 10.1073/pnas.0230374100 pubmed: 12679517 pmcid: 153653

Dreisig K, Kornum B (2016) A critical look at the function of the P2Y

doi: 10.1007/s11302-016-9514-7 pubmed: 27246167 pmcid: 5023629

Kennedy C (2017) P2Y

doi: 10.1007/5584_2017_89

Dănilă MD, Privistirescu A, Duicu OM, Rațiu CD, Angoulvant D, Muntean DM, Sturza A (2017) The effect of purinergic signaling via the P2Y

doi: 10.1007/s11010-017-2973-5 pubmed: 28213772

Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D (2004) ADP receptor P2Y

doi: 10.1161/01.ATV.0000142376.30582.ed pubmed: 15308557

Högberg C, Svensson H, Gustafsson R, Eyjolfsson A, Erlinge D (2010) The reversible oral P2Y

doi: 10.1016/j.ijcard.2008 pubmed: 19176251

Jia Z, Huang Y, Ji X, Sun J, Fu G (2019) Ticagrelor and clopidogrel suppress NF-κB signaling pathway to alleviate LPS-induced dysfunction in vein endothelial cells. BMC Cardiovasc Disord 19(1):318. https://doi.org/10.1186/s12872-019-01287-1

doi: 10.1186/s12872-019-01287-1 pubmed: 31888640 pmcid: 6936058

Han X (2022) Inhibiting P2Y

doi: 10.1002/iid3.697 pubmed: 36169256 pmcid: 9449590

Pels K, Schwimmbeck PL, Rosenthal P, Loddenkemper C, Dang-Heine C, Rauch U, Martens H, Schultheiss HP, Dechend R, Deiner C (2009) Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs. Eur J Clin Invest 39(3):174–182. https://doi.org/10.1111/j.1365-2362.2009.02089.x

doi: 10.1111/j.1365-2362.2009.02089.x pubmed: 19260946

Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84(5):891–896

doi: 10.1055/s-0037-1614133 pubmed: 11127873

Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Hervé C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P, Herbert JM (2006) The active metabolite of Clopidogrel disrupts P2Y

doi: 10.1073/pnas.0510446103 pubmed: 16835302 pmcid: 1635153

Alsaqati M, Latif ML, Chan SL, Ralevic V (2014) Novel vasocontractile role of the P2Y

doi: 10.1111/bph.12473 pubmed: 24138077 pmcid: 3969082

Lazarowski ER, Homolya L, Boucher RC, Harden TK (1997) Identification of an ecto-nucleoside diphosphokinase and its contribution to interconversion of P2 receptor agonists. J Biol Chem 272(33):20402–20407. https://doi.org/10.1074/jbc.272.33.20402

doi: 10.1074/jbc.272.33.20402 pubmed: 9252347

Kennedy C, Leff P (1995) How should P

doi: 10.1016/s0165-6147(00)89010-0

Chootip K, Ness K, Wang Y, Gurney AM, Kennedy C (2002) Regional variation in P2 receptor expression in the rat pulmonary arterial circulation. Br J Pharmacol 137:637–646. https://doi.org/10.1038/sj.bjp.0704915

doi: 10.1038/sj.bjp.0704915 pubmed: 12381677 pmcid: 1573537

Chootip K, Gurney AM, Kennedy C (2005) Multiple P2Y receptors couple to calcium-dependent, chloride channels in smooth muscle cells of the rat pulmonary artery. Resp Res 6:124. https://doi.org/10.1186/1465-9921-6-124

doi: 10.1186/1465-9921-6-124

Syed NH, Tengah A, Paul A, Kennedy C (2010) Characterisation of P2X receptors expressed in rat pulmonary arteries. European J Pharmacol 649:342–348. https://doi.org/10.1016/j.ejphar.2010.09.041

doi: 10.1016/j.ejphar.2010.09.041

Ritter JM, Flower RJ, Henderson G, Loke YK, MacEwan D, Robinson E, Fullerton J (2024) Rang & Dale's Pharmacology, 10

How selective antagonists and genetic modification have helped characterise the expression and functions of vascular P2Y receptors.

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Informations de copyright

Références

Auteurs

Markie O Dales (MO)

Robert M Drummond (RM)

Charles Kennedy (C)

Classifications MeSH